SRC and melanoma: Additional studies showed that SRC-I1 (SRC inhibitor-1) was inactive on patient-derived BRAFV600E mutant melanoma cells resistant to vemurafenib, but enhanced the activity of the pan-RAF inhibitor TAK632 against these cells [22].